Upadacitinib in refractory cutaneous pseudolymphoma: A case report

被引：0

作者：

Danese, Elisabetta ^{[1
]}

Curic, Tea ^{[1
]}

Bellinato, Francesco ^{[1
]}

Colato, Chiara ^{[2
]}

Gisondi, Paolo ^{[1
]}

Girolomoni, Giampiero ^{[1
]}

机构：

[1] Univ Verona, Dept Med, Sect Dermatol & Venereol, Piazzale A Stefani 1, I-37126 Verona, Italy

[2] Univ Verona, Dept Diagnost & Publ Hlth, Sect Pathol, Verona, Italy

来源：

SAGE OPEN MEDICAL CASE REPORTS | 2025年 / 13卷

关键词：

upadacitinib; cutaneous pseudolymphoma; JAK inhibitors;

D O I：

10.1177/2050313X251350370

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cutaneous pseudolymphoma is a benign condition characterized by a reactive B-cell, T-cell or mixed lymphoproliferative process. Different causative agents (e.g. injected substances, tattoo, drugs and insect bites) have been described, but in many cases no cause can be identified; hence, the term idiopathic cutaneous pseudolymphoma. There are no specific guidelines for the treatment of cutaneous pseudolymphoma, and sometimes a few cases are refractory to conventional treatments. We describe a case of a 41-year-old African woman with refractory facial IgG4 pseudolymphoma successfully treated with upadacitinib.

引用

页数：4

共 15 条

[1] JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects [J].

Banerjee, Shubhasree ;

Biehl, Ann ;

Gadina, Massimo ;

Hasni, Sarfaraz ;

Schwartz, Daniella M. .

DRUGS, 2017, 77 (05) :521-546

[2]

Bolognia J., 2024, Dermatology, V5thedn

[3] STAT activation in regulatory CD4+ T cells of patients with primary sclerosing cholangitis [J].

Dold, Leona ;

Kalthoff, Sandra ;

Frank, Leonie ;

Zhou, Taotao ;

Esser, Pia ;

Lutz, Philipp ;

Strassburg, Christian P. ;

Spengler, Ulrich ;

Langhans, Bettina .

IMMUNITY INFLAMMATION AND DISEASE, 2024, 12 (04)

[4] Borrelia burgdorferi-associated cutaneous marginal zone lymphoma:: a clinicopathological study of two cases illustrating the temporal progression of B-burgdorferi-associated B-cell proliferation in the skin [J].

Goodlad, JR ;

Davidson, MM ;

Hollowood, K ;

Batstone, P ;

Ho-Yen, DO .

HISTOPATHOLOGY, 2000, 37 (06) :501-508

[5] JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review [J].

Huang, I-Hsin ;

Chung, Wen-Hung ;

Wu, Po-Chien ;

Chen, Chun-Bing .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[6] Radiotherapy in aggressive cutaneous pseudolymphoma: a case report and review of literature [J].

Joseph, Deepa ;

Irukulla, Monica Malik ;

Ahmed, Syed Fayaz ;

Valiyaveettil, Deepthi ;

Akram, Syed .

RADIATION ONCOLOGY JOURNAL, 2016, 34 (01) :76-80

[7]

Lum Kalisa, 2024, JAAD Case Rep, V46, P95, DOI [10.1016/j.jdcr.2024.02.007, 10.1016/j.jdcr.2024.02.007]

[8] Treatment of Cutaneous Pseudolymphoma: A Systematic Review [J].

Miguel, Diana ;

Peckruhn, Melanie ;

Elsner, Peter .

ACTA DERMATO-VENEREOLOGICA, 2018, 98 (03) :310-317

[9] Cutaneous pseudolymphoma-A review on the spectrum and a proposal for a new classification [J].

Mitteldorf, Christina ;

Kempf, Werner .

JOURNAL OF CUTANEOUS PATHOLOGY, 2020, 47 (01) :76-97

[10] T-cell pseudolymphoma in recurrent herpes simplex virus infection [J].

Mitteldorf, Christina ;

Geissinger, Eva ;

Pleimes, Marc ;

Schoen, Michael P. ;

Kempf, Werner .

JOURNAL OF CUTANEOUS PATHOLOGY, 2019, 46 (10) :717-722

← 1 2 →